CINECA IRIS Institutional Research Information System

FERRARO, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.394
EU - Europa 1.015
AS - Asia 647
AF - Africa 138
OC - Oceania 15
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.376
IT - Italia 349
SE - Svezia 253
CN - Cina 239
SG - Singapore 148
GB - Regno Unito 109
IN - India 92
CI - Costa d'Avorio 78
BG - Bulgaria 77
DE - Germania 67
FI - Finlandia 42
SN - Senegal 35
TR - Turchia 32
VN - Vietnam 32
FR - Francia 25
HK - Hong Kong 23
JP - Giappone 23
NG - Nigeria 23
CA - Canada 16
RU - Federazione Russa 15
AU - Australia 14
KR - Corea 14
BR - Brasile 13
ID - Indonesia 13
IR - Iran 11
PT - Portogallo 11
ES - Italia 10
NL - Olanda 7
BE - Belgio 6
LT - Lituania 6
PL - Polonia 6
IE - Irlanda 5
RO - Romania 5
UA - Ucraina 5
AT - Austria 3
CZ - Repubblica Ceca 3
GR - Grecia 3
IQ - Iraq 3
PK - Pakistan 3
TW - Taiwan 3
CH - Svizzera 2
EU - Europa 2
IL - Israele 2
JO - Giordania 2
MX - Messico 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
CL - Cile 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SI - Slovenia 1
TH - Thailandia 1
Totale 3.225
Salva come PNG Salva come JPEG
Città #
Santa Clara 232
Chandler 148
Shanghai 126
Ashburn 113
Singapore 95
Fairfield 91
Abidjan 78
Sofia 77
Florence 75
London 67
Boardman 62
New York 57
Princeton 50
Serra 37
Wilmington 36
Dakar 35
Lawrence 34
Helsinki 33
Houston 30
Woodbridge 30
Istanbul 29
Milan 29
Kent 27
Medford 27
Lagos 23
Pisa 22
Seattle 22
Cambridge 21
Redwood City 21
Hong Kong 20
Rome 20
Mumbai 19
Massa 18
Ann Arbor 17
Hyderabad 17
Bremen 15
Munich 15
San Diego 13
Ho Chi Minh City 12
Jakarta 12
Ogden 12
Fuzhou 11
Los Angeles 11
Dong Ket 10
Washington 10
Rio de Janeiro 9
Beijing 8
Chicago 8
Livorno 8
Marseille 8
Dallas 7
Naples 7
San Francisco 7
Brussels 6
Jeju City 6
Quanzhou 6
Turin 6
Baia Mare 5
Bengaluru 5
Dearborn 5
Duncan 5
Lappeenranta 5
New Malden 5
Ottawa 5
Tokyo 5
Torres Vedras 5
Birmingham 4
Esslingen am Neckar 4
Madrid 4
Melbourne 4
Mountain View 4
Norwalk 4
Pomona 4
Porto Azzurro 4
Redmond 4
Scarlino 4
Toronto 4
Warsaw 4
Xiamen 4
Bomba 3
Cepagatti 3
Chennai 3
Curitiba 3
Denver 3
Edgware 3
Frankfurt am Main 3
Guarda 3
Jamshedpur 3
Kariya 3
Lisbon 3
Lucca 3
Mount Horeb 3
Niantic 3
Siena 3
St. Catharines 3
Wuhan 3
Ōmura 3
Amman 2
Amsterdam 2
Armentières 2
Totale 2.202
Salva come PNG Salva come JPEG
Nome #
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 113
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 113
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 107
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 99
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 98
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 96
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 96
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 95
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 91
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 90
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 89
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 85
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 85
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 85
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 84
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 82
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 79
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 77
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 73
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 73
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 69
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 68
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 67
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 66
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 65
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 65
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 64
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 64
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 63
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 63
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 62
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 59
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 58
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 57
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 56
null 56
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 54
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 41
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 33
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 31
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 30
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 26
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 26
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 25
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 25
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 23
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 23
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 22
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 22
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 20
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 18
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 18
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 17
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 16
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 15
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data 13
Communicating Drug Safety 10
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 3
Totale 3.323
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.387
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.387
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202085 0 0 0 0 0 0 20 16 16 8 23 2
2020/2021164 6 3 0 7 9 0 7 3 15 0 16 98
2021/2022621 12 16 70 75 89 88 25 32 31 19 44 120
2022/2023818 110 156 57 45 65 68 27 32 179 1 75 3
2023/2024682 17 34 42 16 65 99 85 48 38 37 104 97
2024/2025890 38 87 102 176 149 263 75 0 0 0 0 0
Totale 3.323